Skip to content

TETRAPHASE PHARMACEUTICALS INC

Delisted

CIK 1373707fmd_1QGS758AXKVY1NEQ8QWTGJVB3WManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2006 to Mar 31, 2020, 39 periods

Latest annual · FY2019

Millions
Total revenues
7
Operating income
(68)
Net income
(70)
Free cash flow
(64)

Latest quarter · Q1 FY2020

Millions
Total revenues
2
Operating income
(12)
Net income
(12)
Free cash flow
(11)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2016 to FY2019
+12.8%
Revenue, 5 yearsFY2014 to FY2019
-4.1%
Net income, 5 yearsFY2014 to FY2019
n/m

TETRAPHASE PHARMACEUTICALS INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2019FY2018ChangeSource
Revenue$7.4 million$18.9 million-61%10-K 2020-03-12 · proof
Operating income-$67.5 million-$73.3 million10-K 2020-03-12 · proof
Net income-$70.1 million-$72.2 million10-K 2020-03-12 · proof
Cash from operating activities-$63.7 million-$59.6 million10-K 2020-03-12 · proof
Free cash flow-$63.8 million-$59.8 million10-K 2020-03-12 · proof
Total assets$36.4 million$122.9 million-70.4%10-K 2020-03-12 · proof
Total liabilities$13.2 million$43.3 million-69.4%10-K 2020-03-12 · proof
Cash and cash equivalents$21.2 million$107.8 million-80.3%10-K 2020-03-12 · proof
What was TETRAPHASE PHARMACEUTICALS INC's revenue in fiscal 2019?
TETRAPHASE PHARMACEUTICALS INC reported revenue of $7.4 million for fiscal 2019 (the year ended Dec 31, 2019), against $18.9 million the year before (-61%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
What was TETRAPHASE PHARMACEUTICALS INC's operating income in fiscal 2019?
TETRAPHASE PHARMACEUTICALS INC reported operating income of -$67.5 million for fiscal 2019 (the year ended Dec 31, 2019), against -$73.3 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
What was TETRAPHASE PHARMACEUTICALS INC's net income in fiscal 2019?
TETRAPHASE PHARMACEUTICALS INC reported net income of -$70.1 million for fiscal 2019 (the year ended Dec 31, 2019), against -$72.2 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
What was TETRAPHASE PHARMACEUTICALS INC's cash from operating activities in fiscal 2019?
TETRAPHASE PHARMACEUTICALS INC reported cash from operating activities of -$63.7 million for fiscal 2019 (the year ended Dec 31, 2019), against -$59.6 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
What was TETRAPHASE PHARMACEUTICALS INC's free cash flow in fiscal 2019?
TETRAPHASE PHARMACEUTICALS INC reported free cash flow of -$63.8 million for fiscal 2019 (the year ended Dec 31, 2019), against -$59.8 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
What are TETRAPHASE PHARMACEUTICALS INC's total assets?
As of Dec 31, 2019, TETRAPHASE PHARMACEUTICALS INC reported total assets of $36.4 million, against $122.9 million a year earlier (-70.4%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
What are TETRAPHASE PHARMACEUTICALS INC's total liabilities?
As of Dec 31, 2019, TETRAPHASE PHARMACEUTICALS INC reported total liabilities of $13.2 million, against $43.3 million a year earlier (-69.4%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC
What are TETRAPHASE PHARMACEUTICALS INC's cash and cash equivalents?
As of Dec 31, 2019, TETRAPHASE PHARMACEUTICALS INC reported cash and cash equivalents of $21.2 million, against $107.8 million a year earlier (-80.3%). Source: the 10-K filed with the SEC on Mar 12, 2020. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1373707&period_type=annual&limit=5"

Information only, not investment advice.